Search

Learn how researchers engineered CAR T cells to work better by using a mutation in a gene called c-KIT that drives cancer cell growth.

… Monday, June 19, 2023 Chimeric antigen receptor (CAR) T cell therapy , an immunotherapy that uses genetically modified immune cells, has shown great promise for the treatment of blood cancers such as  leukemia  and  lymphoma . However, this type of immunotherapy has so far been much less effective against

The study of some victims exposed to ionizing radiation from the 1986 Chernobyl nuclear power plant accident is yielding new information about how radiation-induced thyroid cancer develops.

… Wednesday, November 13, 2013 Summary The study of some victims exposed to ionizing radiation from the 1986 Chernobyl nuclear power plant accident is yielding new information about how radiation-induced thyroid cancer develops. The 1986 Chernobyl nuclear power plant disaster was the worst nuclear accident

Convection enhanced delivery, an innovative technique that directly infuses a therapeutic agent into a brain tumor through a cannula, bypassing the blood-brain barrier, is safe and feasible for treating diffuse intrinsic pontine glioma in children.

… Friday, August 14, 2020 Convection enhanced delivery (CED), an innovative technique that directly infuses a therapeutic agent into a brain tumor through a cannula, bypassing the blood-brain barrier (BBB), is safe and feasible for treating diffuse intrinsic pontine glioma (DIPG), according to our experience

Memorial Sloan Kettering Cancer Center (MSK) is collaborating with Triomics, an oncology-focused generative artificial intelligence company, to deploy Triomics’ artificial intelligence (AI)-powered clinical trial matching and screening platform in MSK’s active clinical trials.

… Tuesday, November 4, 2025 Memorial Sloan Kettering Cancer Center (MSK) is collaborating with Triomics, an oncology-focused generative artificial intelligence company, to deploy Triomics’ artificial intelligence (AI)-powered clinical trial matching and screening platform in MSK’s active clinical trials

Learn about the latest research on why more young adults are developing cancer, from investigators across MSK.

… Monday, January 5, 2026 It’s a disturbing mystery that has drawn the attention of investigators from across Memorial Sloan Kettering Cancer Center (MSK). Why are a growing number of young people under 50 being diagnosed with over a dozen forms of cancer around the world? This trend is especially worrying

Obtenga las últimas actualizaciones de investigación de investigadores de MSK sobre por qué tantos adultos jóvenes tienen cáncer.

… Monday, January 5, 2026 Es un misterio inquietante que ha llamado la atención de los investigadores de todo Memorial Sloan Kettering Cancer Center (MSK). ¿Por qué cada vez más se diagnostica a jóvenes menores de 50 años con más de una decena de formas de cáncer en todo el mundo? Esta tendencia es especialmente

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published in The New England Journal of Medicine and presented at the 49th Annual Meeting of the American Society of Clinical Oncology.

… Sunday, June 2, 2013 The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma , according to results from a Phase I trial simultaneously published today in The New England

New MSK research finds a way to package protein-degrading drugs called PROTACs into nanoparticles that target blood vessels within solid tumors; identifies genomic markers that predict whether precancerous blood conditions will turn into multiple myeloma; develops a data-driven approach that could catch lymphedema earlier; and shows that nurse-led palliative care delivered by phone could serve as a scalable model.

… Tuesday, December 16, 2025   New research from Memorial Sloan Kettering Cancer Center (MSK) finds a way to package protein-degrading drugs called PROTACs into nanoparticles that target blood vessels within solid tumors; identifies genomic markers that predict whether precancerous blood conditions will

Learn how MSK’s Antibiotic Management Program is leading the way in ensuring that antibiotics and other antimicrobial drugs are used responsibly.

… Wednesday, May 22, 2019 Summary In this Q & A, infectious disease expert Susan Seo discusses MSK’s Antibiotic Management Program. It ensures that antibiotics and other antimicrobial drugs are used responsibly. The rapid emergence of drug-resistant microorganisms is “a global crisis that threatens a century

MSK is proud to announce that four Sloan Kettering Institute (SKI) researchers have been named 2024 Marie-Josée Kravis Women in Science Endeavor (Kravis WISE) fellowship grant recipients.

… Thursday, February 29, 2024 Each year, the Marie-Josée Kravis Women in Science Endeavor (WISE) initiative awards several fellowships to female graduate students and postdoctoral fellows to support their research at Memorial Sloan Kettering Cancer Center (MSK). The awards are announced in March, to coincide